切换至 "中华医学电子期刊资源库"

中华肾病研究电子杂志 ›› 2016, Vol. 05 ›› Issue (06) : 265 -268. doi: 10.3877/cma.j.issn.2095-3216.2016.06.006

所属专题: 文献

论著

黄葵胶囊联合健脾益肾方对慢性肾脏病脾肾阳虚型患者的疗效观察
曹春华1, 王娜1, 于亚萍1, 丛旭东2, 马腾1, 彭德熹1, 周颖1, 顾雪琴1, 袁成业1,()   
  1. 1. 225300 江苏省南京中医药大学附属泰州市中医院肾病科
    2. 江苏泰州,江苏苏中药业集团股份有限公司
  • 收稿日期:2016-11-18 出版日期:2016-12-28
  • 通信作者: 袁成业
  • 基金资助:
    江苏省第四期"333工程"科研项目资助计划(BRA2014184); 泰州市科技支撑计划(社会发展)(2014TS007)

Effect of Huangkui capsule combined with Jianpiyishen decoction on CKD patients with Pishengyangxu syndrome

Chunhua Cao1, Na Wang1, Yaping Yu1, Xudong Cong2, Teng Ma1, Dexi Peng1, Ying Zhou1, Xueqin Gu1, Chengye Yuan1,()   

  1. 1. Department of Nephrology, Taizhou Hospital of Chinese Medicine Affiliated to Nanjing University of Chinese Medicine, Taizhou 225300, Jiangsu Province, China
    2. SZYY Group Pharmaceutical Ltd, Taizhou 225300, Jiangsu Province, China
  • Received:2016-11-18 Published:2016-12-28
  • Corresponding author: Chengye Yuan
  • About author:
    Corresponding author: Yuan Chengye, Email:
引用本文:

曹春华, 王娜, 于亚萍, 丛旭东, 马腾, 彭德熹, 周颖, 顾雪琴, 袁成业. 黄葵胶囊联合健脾益肾方对慢性肾脏病脾肾阳虚型患者的疗效观察[J]. 中华肾病研究电子杂志, 2016, 05(06): 265-268.

Chunhua Cao, Na Wang, Yaping Yu, Xudong Cong, Teng Ma, Dexi Peng, Ying Zhou, Xueqin Gu, Chengye Yuan. Effect of Huangkui capsule combined with Jianpiyishen decoction on CKD patients with Pishengyangxu syndrome[J]. Chinese Journal of Kidney Disease Investigation(Electronic Edition), 2016, 05(06): 265-268.

目的

观察黄葵胶囊联合健脾益肾方对慢性肾脏病(CKD3-4期)脾肾阳虚型的临床疗效。

方法

58例患者随机分为治疗组(28例)和对照组(30例),两组患者均接受西医基础治疗及自拟健脾益肾方治疗,方剂1剂/d,100 ml/次煎服,2次/d,连用3个月,治疗组在此基础上加黄葵胶囊治疗,5粒/次口服,3次/d,连用3个月。于治疗前、治疗3个月时检测血液相关指标:Hb、Alb、TC、TG、BUN、Cr、UA、eGFR、CRP及β2微球蛋白(β2-MG)、血清超氧化物歧化酶(SOD)、丙二醛(MDA)、内皮素(ET)、一氧化氮(NO)。

结果

治疗前以上两组相关指标差异无统计学意义(P> 0.05);治疗后两组收缩压、舒张压、TC、TG、BUN、Cr、UA、β2-MG、CRP、MDA、ET显著降低,Hb、Alb、NO、SOD、eGFR显著升高,差异均有统计学意义(P<0.05);与对照组比较,治疗组于治疗3个月后舒张压、TC、TG、BUN、Cr、UA、β2-MG、CRP、MDA、ET降低更明显,Hb、Alb、NO、SOD、eGFR升高更明显,差异均有统计学意义(P<0.05)。治疗3个月后,治疗组中医脾肾阳虚型主证表现消失,标实证表现明显减少,尤以湿热证减少明显;对照组脾肾阳虚型主证及标实证表现减少。

结论

黄葵胶囊联合健脾益肾方治疗慢性肾脏病(CKD3-4期)脾肾阳虚型合并湿热的临床疗效优于单纯使用健脾益肾方。

Objective

To observe the clinical effect of Huangkui capsule combined with Jianpiyishen decoction on chronic kidney disease (CKD stage 3-4) patients with Pishengyangxu syndrome.

Methods

58 patients were randomly divided into treatment group (28 cases) and control group (30 cases). Both groups received the basic treatment of western medicine and the Jianpiyishen recipe (1 dose/day, decoction 100 ml/time, twice a day for 3 months). The treatment group was added with oral Huangkui capsule, 5 capsules/time, thrice a day for 3 months. Before treatment, and 3 months after the treatment, the following were detected: Hb, Alb, TC, TG, BUN, Cr, UA, eGFR, C-reactive protein (CRP), beta 2 microglobulin (β2-MG), serum superoxide dismutase (SOD), malondialdehyde (MDA), endothelin (ET), and nitric oxide (NO).

Results

Compared with the control group, the treatment group showed significantly higher levels of Hb, Alb, NO, SOD, and eGFR (P<0.05) 3 months after the treatment, but showed significantly lower levels of TC, TG, BUN, Cr, UA, CRP, MDA, β2-MG, ET, and DBP (P<0.05), with all the differences being statistically significant. Both the primary and secondary manifestations of TCM Pishengyangxu syndrome disappeared, and the secondary sthenia syndrome manifestations were reduced.

Conclusion

The effect of Huangkui capsule combined with Jianpiyishen formula on CKD (stage 3-4) patients with Pishengyangxu syndrome was better than that of Jianpiyishen recipe alone.

表1 治疗组与对照组患者治疗前后各检测指标比较(±s)
组别 例数 治疗前
SBP(mmHg) DBP(mmHg) Hb(g/L) Alb(g/L) TC(mmol/L) TG(mmol/L) BUN(mmol/L) Cr(μmol/L)
治疗组 28 143±5.0 92±5.0 84.2±11.1 34.1±5.1 4.4±1.3 1.6±0.92 15.5±5.3 290.9±55.8
对照组 30 141±4.0 90±3.0 84.3±12.1 35.5±4.3 4.3±1.3 1.7±0.87 14.5±5.2 285.7±43.6
t ? 1.688 1.862 0.033 1.133 0.293 0.426 0.720 0.397
P ? 0.098 0.063 0.970 0.262 0.771 0.672 0.471 0.693
组别 例数 治疗前
UA(μmol/L) eGFR[ml/(min·1.73 m2)] CRP(mg/L) β2-MG(mg/L) SOD(μg/L) MDA(μmol/L) ET(ng/L) NO(mmol/L)
治疗组 28 389.5±99.5 46.3±9.4 9.9±7.2 22.0±6.9 88.4±6.2 7.1±0.9 149.0±29.8 13.9±4.3
对照组 30 390.4±96.6 44.7±8.5 9.8±7.4 23.1±7.7 86.1±6.6 7.2±1.0 158.1±30.1 14.8±4.5
t ? 0.035 0.691 0.052 0.572 1.366 0.3998 1.1568 0.777
P ? 0.922 0.499 0.959 0.570 0.178 0.6918 0.253 0.440
组别 例数 治疗后3个月
SBP(mmHg) DBP(mmHg) Hb(g/L) Alb(g/L) TC(mmol/L) TG(mmol/L) BUN(mmol/L) Cr(μmol/L)
治疗组 28 130±9.0a 80±5.0a 99.4±12.5a 51.5±4.5a 3.5±1.0a 1.2±0.67a 7.8±3.3a 166.3±22.5a
对照组 30 128±6.0a 79±6.0a 91.4±13.0a 47.5±3.2a 4.2±1.2a 1.7±0.98a 9.8±4.0a 198.6±77.4a
t ? 1.002 4.121 2.351 3.922 2.404 2.252 2.069 2.125
P ? 0.321 0.001 0.022 <0.001 0.020 0.028 0.043 0.038
组别 例数 治疗后3个月
UA(μmol/L) eGFR[ml/(min·1.73 m2)] CRP(mg/L) 血β2-MG(mg/L) SOD(μg/L) MDA(μmol/L) ET(ng/L) NO(mmol/L)
治疗组 28 308.7±66.5a 65.4±12.6a 4.7±6.2a 6.1±3.8a 98.2±6.5a 4.3±0.5a 113±27.5a 26.8±4.4a
对照组 30 349.8±70.5a 58.4±11.6a 8.3±6.1a 10.5±4.7a 94.1±7.2a 5.5±0.7a 128±21.3a 23.8±4.5a
t ? 2.280 2.203 2.228 3.904 2.271 7.465 2.323 2.564
P ? 0.026 0.016 0.030 <0.001 0.027 <0.001 0.024 0.013
1
王海燕.提高对于慢性肾脏病的认识、临床工作和研究水平[J].中华肾脏病杂志,2005,1(1):1.
2
何立群.肾脏病中医辨治新探[M].北京:人民卫生出版社,2009.
3
郑筱萸.中药新药临床研究指导原则(试行)[S],北京:中国医药科技出版社,2002.
4
展俊平,郑光,姜淼,等.文本挖掘探索慢性肾小球肾炎"证-症-方-药"相应规律[J].中国实验方剂学杂志,2013,19(3):315-317.
5
蒋易容,张紫媛,文集,等.黄葵胶囊治疗lgA肾病疗效和安全性的系统评价[J].中国循证医学杂志,2012,12(9):1135.
6
曹珊,胡江平,孙新宇.黄葵胶囊对糖尿病肾病血脂成分的影响[J].中国实验方剂学杂志,2011,17(5):229-232.
7
周红霞,赵丽萍,葛婷婷,等.黄葵胶囊对慢性肾脏疾病患儿肾小管功能的影响[J].现代中西医结合杂志,2011,20(23):2930-2933.
8
徐延平,宋剑,李彦华,等.黄葵胶囊对5/6肾切除大鼠肾问质纤维化中炎性因子表达的影响[J].中国中西医结合肾病杂志,2012,13(6):533-534.
9
Casado A, Ferndndez ME, Casado MC, et al. Lipid peroxidation and antioxidant enzyme activities in vascular and Alzheimer dementias [J].Neurochem Res, 2008, 33(3):450-458.
10
袁志柳,刘兴德,陈保林,等.缺血后处理对缺血再灌注大鼠心肌梗塞面积、CK、MDA及SOD的影响[J].微循环杂志,2006,16(1):27-28.
No related articles found!
阅读次数
全文


摘要